NCT06812910

Brief Summary

Study Title: SUNRISE Study: Urban and Island Experiences of HIV Treatment and Stigma What is this study about? This study aims to understand how living in urban areas versus islands affects the experiences of people living with HIV (PLWH) in Portugal. Specifically, the investigators want to explore how stigma and mental health (such as depression and anxiety) differ between these two settings. The investigators are also interested in understanding how the number of pills a person takes daily (called "pill burden") impacts their mental health and satisfaction with treatment. Why is this study important? Stigma related to HIV can make it harder for people to stick to their treatment and can negatively affect their mental health and overall well-being. By comparing urban and island settings, the investigators hope to identify unique challenges faced by PLWH in different environments. This information will help the investigators to develop better strategies to support people living with HIV, no matter where they live. Who can participate? Adults (18 years or older) who have been diagnosed with HIV. People who have been on antiretroviral therapy (HIV treatment) for at least six months. Individuals living in urban areas or island region. What will happen during the study? Participants will complete a one-time interview during their regular HIV care visit. The interview will include questions about: Their experiences with HIV-related stigma. Their mental health (including depression and anxiety). Their satisfaction with their current HIV treatment. The number of pills they take daily and how this affects their daily life. All information will be kept confidential, and participation is voluntary. What are the potential benefits of participating? This study will help to understand the challenges faced by people living with HIV in different parts of Portugal. This knowledge can lead to improved support services and treatment options for PLWH in the future. What are the risks of participating? There are no physical risks associated with this study. However, some questions may touch on sensitive topics, such as stigma or mental health. How will the results be used? The results of this study will be shared with the scientific community, healthcare providers, and organizations that support people living with HIV. The goal is to use this information to improve care and reduce stigma for PLWH in Portugal and beyond. Who is conducting this study? This study is led by researchers from the Faculty of Medicine of Lisbon, in collaboration with hospitals in Portugal mainland, the Azores, and Madeira.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 1, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 6, 2025

Completed
23 days until next milestone

Study Start

First participant enrolled

March 1, 2025

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 27, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 27, 2026

Completed
Last Updated

February 19, 2025

Status Verified

February 1, 2025

Enrollment Period

12 months

First QC Date

February 1, 2025

Last Update Submit

February 15, 2025

Conditions

Keywords

HIVHIV related stigmamental healthpill burdentreatment experience

Outcome Measures

Primary Outcomes (1)

  • Levels of HIV-Related Stigma in Urban versus Island Settings

    This outcome measures the levels of HIV-related stigma experienced by individuals living with HIV (PLWH) in urban and island settings in Portugal. Stigma is assessed using a validated HIV Stigma Scale, which evaluates perceived and internalized stigma (range: 0-48, where higher scores indicate greater perceived stigma). The results will be compared between the two geographic cohorts to identify differences in stigma experiences.

    Cross-sectional assessment at baseline (one-time measurement during study enrollment).

Secondary Outcomes (5)

  • Prevalence of Depression and Anxiety in Urban versus Island PLWH

    Cross-sectional assessment at baseline (one-time measurement during study enrollment).

  • Association Between Stigma and Mental Health Indicators (Depression and Anxiety)

    Cross-sectional assessment at baseline (one-time measurement during study enrollment).

  • Association Between Pill Burden and Mental Health Impact in People Living With HIV

    Cross-sectional assessment at baseline (one-time measurement during study enrollment).

  • Association Between HIV Treatment Satisfaction and Stigma/Mental Health Indicators

    Cross-sectional assessment at baseline (one-time measurement during study enrollment).

  • Assessment and comparison of HIV-Related Knowledge between Urban versus Island Settings

    Cross-sectional assessment at baseline (one-time measurement during study enrollment).

Study Arms (2)

Urban Cohort

People living with HIV (PLWH) who receive care in urban centers.

Island Cohort

People living with HIV (PLWH) who receive care in island regions (Azores and Madeira).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population consists of individuals living with HIV (PLWH) who are receiving care in urban and island settings in Portugal. Participants must be 18 years of age or older, diagnosed with HIV, and on antiretroviral therapy (ART) for at least six months. They must also be on a daily oral treatment regimen (single or multiple pills) and able to provide informed consent.

You may qualify if:

  • Individuals diagnosed with HIV
  • Aged 18 years or older.
  • On antiretroviral therapy (ART) for at least six months.
  • On a daily oral treatment regimen (single or multiple pills).
  • Able to provide informed consent.

You may not qualify if:

  • Individuals under 18 years of age.
  • Individuals who have switched antiretroviral regimen in the previous six months.
  • Individuals unable to provide informed consent (e.g., due to cognitive impairment or lack of capacity).
  • Individuals with limited understanding of the study procedures or questionnaires (e.g., language barriers or cognitive limitations).
  • Individuals who are incarcerated or deprived of liberty.
  • Pregnant individuals.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unidade Local de Saúde de Santa Maria

Lisbon, Portugal

Location

MeSH Terms

Conditions

Social StigmaDepressionAnxiety DisordersPsychological Well-Being

Condition Hierarchy (Ancestors)

Social BehaviorBehaviorBehavioral SymptomsMental DisordersPersonal Satisfaction

Central Study Contacts

Fábio Cota Medeiros, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
NETWORK
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 1, 2025

First Posted

February 6, 2025

Study Start

March 1, 2025

Primary Completion

February 27, 2026

Study Completion

February 27, 2026

Last Updated

February 19, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations